Figure 2From: Efficacy and safety of the human anti-IL-1beta monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, phase II, dose-finding study ACR20 and ACR50 responders in the treatment groups. Analysis based on 28-joint counts. *p < 0.05 vs. placebo.Back to article page